Iron: The Secret Ingredient Breaking PARPi Resistance.

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-08-02 DOI:10.1158/2159-8290.CD-24-0775

Hamed Alborzinia, José Pedro Friedmann Angeli

引用次数: 0

Abstract

PARP inhibitors (PARPi) are used as a first-line treatment option for cancers with BRCA1/2 mutations, yet a significant number of patients show a limited response to these agents. In the present study, Lei and colleagues demonstrate that PARPi promote increased ferroptosis sensitivity and this can be exploited therapeutically to improve the response to PARPi, marking an important therapeutic concept to exploit ferroptosis-based strategies in clinical settings. See related article by Lei et al., p. 1476 (2).

查看原文本刊更多论文

铁：打破 PARPi 抗药性的秘密成分。

PARP抑制剂（PARPi）被用作BRCA1/2基因突变癌症的一线治疗方案，但相当多的患者对这些药物的反应有限。在本研究中，Lei及其同事证明了PARPi能促进铁蛋白沉积敏感性的增加，而这可以被治疗性地利用来改善对PARPi的反应，这标志着在临床环境中利用基于铁蛋白沉积的策略是一个重要的治疗概念。见 Lei 等人的相关文章，第 1476 页（2）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.